FDA Clears AutoGenomics' CYP2C19 Assay | GenomeWeb

This article has been updated to clarify the intended use of the assay.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – AutoGenomics today said that the US Food and Drug Administration has given 510(k) clearance for its Infiniti CYP2C19 assay.

The test detects three genetic variants, *2, *3, and *17 of the CYP450 2C19 gene. The test is for use on AutoGenomics' Infiniti Analyzer molecular diagnostic platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.